Actively Recruiting
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
Led by University of California, San Francisco · Updated on 2025-04-02
20
Participants Needed
1
Research Sites
140 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this proof-of-concept clinical trial is to determine whether cardiac rehabilitation improves exercise capacity and chronotropic (heart rate) response to exercise among people with Long COVID. The study will include individuals with confirmed SARS-CoV-2 infection, symptoms not present prior to COVID-19 that are persistent for at least 3 months after acute infection ("Long COVID"), and who have reduced exercise capacity less than predicted and reduced heart rate response during cardiopulmonary exercise testing (CPET). In addition to the primary outcome of change in peak VO2, secondary outcomes will include change in symptoms including autonomic symptoms (COMPASS-31), anxiety (GAD-7), depression (PHQ-9), endothelial function with brachial artery flow-mediated dilation, and satisfaction (net-promotor score).
CONDITIONS
Official Title
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Previously confirmed positive SARS-CoV-2 test by nucleic acid amplification, antigen testing, or nucleocapsid antibody with documentation
- Persistent symptoms attributed to COVID-19 lasting at least 90 days after symptom onset
- Reduced exercise capacity less than 100% predicted or self-reported decrease compared to before COVID-19
- Willing and able to participate in cardiac rehabilitation including attending at least 12 in-person sessions at UCSF Parnassus
- Agree to participate in the LIINC Study including the cardiovascular substudy if not already enrolled
You will not qualify if you...
- Pregnant or planning to become pregnant during the study
- Pre-existing congenital heart disease, heart failure, pulmonary hypertension, heart or lung transplant, or cardiac valve surgery
- Recent myocardial infarction, coronary artery bypass graft, or new heart failure diagnosis with ejection fraction below 40% within 90 days before enrollment
- Acute myocarditis diagnosed less than 90 days prior
- Atrial fibrillation, atrial flutter, or other arrhythmias requiring antiarrhythmic medication
- Current use of beta-blockers, certain calcium channel blockers, or ivabradine
- Having an implanted pacemaker or defibrillator
- Chronic lung disease requiring home oxygen
- Unable to ride a sitting bicycle for cardiopulmonary exercise testing
- Severe post-exertional malaise or worsening symptoms that prevent cardiac rehabilitation
- Medical or psychological conditions that prevent safe participation as determined by the Principal Investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94110
Actively Recruiting
Research Team
M
Matthew S Durstenfeld, MD MAS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here